PETV
PetVivo Holdings, Inc.1.1600
-0.0300-2.52%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q3 '26
Dodges guidance, low-capex AI details.
Q&A largely reinforced prepared remarks on revenue softness from skipped December promotions and PrecisePRP mix shift, but management sidestepped prior $2M-$2.5M FY guidance without reaffirmation, blaming distributor loading changes. They detailed sales enhancements like reintroducing promotions, combo-use education, and outsourcing to a third-party firm for broader distributor reach. On PetVivo AI rollout, CapEx stays minimal as Digital Landia handles support, with VGP onboarding via webinars and revenue as monthly SaaS starting Q1 FY2027. No forecasts given. Investors watch AI adoption rates. Management stayed qualitative.
Key Stats
Market Cap
38.95MP/E (TTM)
-Basic EPS (TTM)
-0.40Dividend Yield
0%Recent Filings
8-K
PetVivo raises $1M equity
PetVivo Holdings secured $1M in equity financing on March 13, 2026, issuing 1.25M restricted common shares at $0.80 per unit (each with a warrant exercisable at $1.10 through 2029); $400K received immediately, $600K due by April 15. Funds target Spryng commercialization, product development, trials, and working capital. Investor holds $1.5M option through June 15. Shares dilute existing holders.
8-K
Investor presentation furnished
10-Q
Q3 FY2026 results
PetVivo's Q3 FY2026 revenue fell 51% y/y to $286K from a prior promotion, yet YTD held steady at $887K versus $908K, blending Spryng and new PrecisePRP sales via Vedco (72% YTD). Gross margin contracted to 50.6% from 89.5% on lower-margin PrecisePRP, driving operating loss wider to $2.2M (up 25% y/y) and net loss to $2.2M, matching operating with no material other items; diluted EPS improved to $(0.07) from $(0.09) on 33.7M shares (anti-dilutive). Cash dwindled to $18K after $5.3M ops burn, offset by $5.1M financing including $4.4M Series B; all debt cleared, leases cut to $71K. Signed VetStem exclusive license in Feb 2025 for $2M (cash/stock/future payments, 60-month amortization). Government shutdowns risk supply and funding.
8-K
Director resigns, board shrinks
8-K
Furnishes investor presentation
PetVivo Holdings filed an 8-K on January 22, 2026, furnishing its January 2026 Investor Presentation under Regulation FD for use at investor conferences. Company reps plan to share this material—possibly updated—via presentations and its website. No duty to update. Filing makes no materiality admission.
BVS
Bioventus Inc.
7.52+0.02
IVP
Inspire Veterinary Partners, In
0.05-0.00
LIVN
LivaNova PLC
63.08+0.02
PETS
PetMed Express, Inc.
3.90+1.03
PTPI
Petros Pharmaceuticals, Inc.
0.01-0.00
RBOT
Vicarious Surgical Inc.
2.43-0.04
RDGL
Vivos Inc.
0.07-0.00
VVOS
Vivos Therapeutics, Inc.
2.02+0.00
ZIVO
Zivo Bioscience, Inc.
9.00+0.00
ZOMDF
Zomedica Corp.
0.11+0.00